{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:00:29Z","timestamp":1785261629885,"version":"3.55.0"},"reference-count":67,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Resistance to antimalarial drugs has posed a significant challenge to global efforts to control and eliminate malaria. Partial artemisinin resistance has been observed in East Africa, a region that has been a historical hotspot for antimalarial drug resistance across the continent. Consequently, this review assesses the extent of non-synonymous mutations mediating artemisinin resistance, the varieties of these mutations, and their effects on treatment outcomes in East Africa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Studies reporting artemisinin resistance (samples collected between 2014 and 2024), particularly the\n                      <jats:italic>Pf-Kelch13<\/jats:italic>\n                      mutation among malaria patients in East Africa, were searched through the Medline, Cochrane Central Register of Controlled Trials (CENTRAL), LILACS, and EMBASE online databases. The protocol for the review was registered at PROSPERO (Reference number: CRD42024602752). Two independent reviewers extracted data. Potential publication bias was assessed using a funnel plot. Pooled proportion estimates were calculated using a random-effects model, and heterogeneity was assessed using I\n                      <jats:sup>2<\/jats:sup>\n                      statistics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-four (24) studies were deemed eligible for data extraction. The heterogeneity among the studies included in the meta-analysis was high (I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009&gt;\u200995% and p\u2009&lt;\u20090.01). The overall estimated pooled proportions of non-synonymous\n                      <jats:italic>Pf-Kelch13<\/jats:italic>\n                      mutations, using the random effects model, were 5.0% (95% CI 3.0%\u20137.0%), with the pooled proportion estimates being higher in Rwanda and Uganda (10.0%, 95% CI 4.0%\u201316.0%) and (10.0%, 95% CI 6.0%\u201314.0%), respectively. Subgroup analysis (per mutation type) revealed that R561H and A675V were the most prevalent non-synonymous mutations (9.0%, 95% CI 5.0%\u201315.0% and 7.0%, 95% CI 4.0%\u201310.0%, respectively). Patients harbouring parasites with\n                      <jats:italic>Pf-Kelch13<\/jats:italic>\n                      non-synonymous mutations were significantly more likely to experience treatment failure than those harbouring wild\n                      <jats:italic>P. falciparum<\/jats:italic>\n                      parasites (Log OR: \u22122.06, 95% CI, \u22122.71\u20131.41).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The prevalence of\n                      <jats:italic>Pf-Kelch13<\/jats:italic>\n                      non-synonymous mutations known to be associated with artemisinin resistance was significant. The most common mutations identified were R561H and A675V. Continued molecular surveillance and coordinated efforts are essential to contain the partial artemisinin resistance in the East African region and prevent its spread across the continent.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0354429","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:23:11Z","timestamp":1785259391000},"page":"e0354429","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasmodium falciparum non-synonymous Kelch13 mutations mediating artemisinin resistance in East Africa: A systematic review and meta-analysis: 2014\u20132024"],"prefix":"10.1371","volume":"21","author":[{"given":"Anthony","family":"Kapesa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9694-9293","authenticated-orcid":true,"given":"Vito","family":"Baraka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Mwaiswelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0154-8858","authenticated-orcid":true,"given":"Maria","family":"Zinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5237-2904","authenticated-orcid":true,"given":"Karol J.","family":"Marwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8891-758X","authenticated-orcid":true,"given":"Eliningaya J.","family":"Kweka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erasmus","family":"Kamugisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"pone.0354429.ref001","volume-title":"World malaria report 2024: addressing inequity in the global malaria response","author":"WHO","year":"2024"},{"issue":"1","key":"pone.0354429.ref002","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40249-019-0524-x","article-title":"Are malaria elimination efforts on right track? An analysis of gains achieved and challenges ahead","volume":"8","author":"S Dhiman","year":"2019","journal-title":"Infect Dis Poverty"},{"issue":"10","key":"pone.0354429.ref003","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","article-title":"Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda","volume":"26","author":"A Uwimana","year":"2020","journal-title":"Nat Med"},{"key":"pone.0354429.ref004","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1475-2875-5-34","article-title":"Invasion of Africa by a single pfcrt allele of South East Asian type","volume":"5","author":"F Ariey","year":"2006","journal-title":"Malar J"},{"issue":"12","key":"pone.0354429.ref005","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1093\/infdis\/jir664","article-title":"Limited geographical origin and global spread of sulfadoxine-resistant dhps alleles in Plasmodium falciparum populations","volume":"204","author":"T Mita","year":"2011","journal-title":"J Infect Dis"},{"issue":"8","key":"pone.0354429.ref006","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01659-23","article-title":"Indigenous emergence and spread of kelch13 C469Y artemisinin-resistant Plasmodium falciparum in Uganda","volume":"68","author":"P Awor","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"pone.0354429.ref007","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41564-023-01461-4","article-title":"Plasmodium falciparum resistant to artemisinin and diagnostics have emerged in Ethiopia","volume":"8","author":"AA Fola","year":"2023","journal-title":"Nat Microbiol"},{"key":"pone.0354429.ref008","volume-title":"National policy for malaria treatment","author":"Ministry of Gender LaSD","year":"2005"},{"key":"pone.0354429.ref009","volume-title":"National guidelines for the treatment of malaria in Rwanda","author":"Rwanda Ro","year":"2006"},{"key":"pone.0354429.ref010","volume-title":"National guidelines for the diagnosis, treatment and prevention of malaria for health workers in Kenya","author":"M Kenya","year":"2006"},{"key":"pone.0354429.ref011","volume-title":"Malaria treatment guideline. Dar es salaam","author":"Welfare MoHaS","year":"2006"},{"key":"pone.0354429.ref012","article-title":"The MARC SE-Africa Dashboard: Joining forces to counteract emerging antimalarial resistance in south and east Africa","author":"S van Wyk","year":"2025","journal-title":"medRxiv"},{"issue":"6","key":"pone.0354429.ref013","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.trstmh.2004.09.013","article-title":"Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria","volume":"99","author":"C Falade","year":"2005","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pone.0354429.ref014","volume-title":"Guidelines for the treatment of malaria","author":"Organization WH","year":"2015"},{"issue":"13","key":"pone.0354429.ref015","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","article-title":"Evidence of Artemisinin-Resistant Malaria in Africa","volume":"385","author":"B Balikagala","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0354429.ref016","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa2211803","article-title":"Evolution of Partial Resistance to Artemisinins in Malaria Parasites in Uganda","volume":"389","author":"MD Conrad","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0354429.ref017","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","article-title":"Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study","volume":"21","author":"A Uwimana","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"pone.0354429.ref018","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S1473-3099(24)00362-1","article-title":"Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance","volume":"24","author":"DS Ishengoma","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"7481","key":"pone.0354429.ref019","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature12876","article-title":"A molecular marker of artemisinin-resistant Plasmodium falciparum malaria","volume":"505","author":"F Ariey","year":"2014","journal-title":"Nature"},{"issue":"1","key":"pone.0354429.ref020","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12936-019-2701-6","article-title":"K13-propeller gene polymorphisms in Plasmodium falciparum parasite population in malaria affected countries: a systematic review of prevalence and risk factors","volume":"18","author":"M Ocan","year":"2019","journal-title":"Malar J"},{"key":"pone.0354429.ref021","article-title":"The emergence of artemisinin partial resistance in Africa: how do we respond?","author":"PJ Rosenthal","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"pone.0354429.ref022","volume-title":"Artemisinin resistance and artemisinin-based combination therapy efficacy: status report","author":"Organization WH","year":"2018"},{"issue":"1","key":"pone.0354429.ref023","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12936-024-04848-8","article-title":"Emergence of Plasmodium falciparum strains with artemisinin partial resistance in East Africa and the Horn of Africa: is there a need to panic?","volume":"23","author":"A Assefa","year":"2024","journal-title":"Malar J"},{"key":"pone.0354429.ref024","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"88","author":"MJ Page","year":"2021","journal-title":"Int J Surg"},{"key":"pone.0354429.ref025","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad149","article-title":"Examining the early distribution of the artemisinin-resistant Plasmodium falciparum kelch13 R561H mutation in areas of higher transmission in Rwanda.","volume-title":"Open Forum Infectious Diseases","author":"R Kirby","year":"2023"},{"key":"pone.0354429.ref026","volume-title":"National Heart Lung, and Blood Institute. Study quality assessment tools","author":"Health NIo","year":"2018"},{"key":"pone.0354429.ref027","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f4040","article-title":"Meta-analyses: heterogeneity and subgroup analysis","volume":"346","author":"P Sedgwick","year":"2013","journal-title":"BMJ"},{"key":"pone.0354429.ref028","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/B978-0-443-13428-9.00012-4","article-title":"Publication bias and funnel plot","volume-title":"Systematic Review and Meta-Analysis","author":"M Sadeghi","year":"2025"},{"issue":"5","key":"pone.0354429.ref029","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.4269\/ajtmh.16-0483","article-title":"Artemisinin resistance\u2013associated K13 polymorphisms of Plasmodium falciparum in Southern Rwanda, 2010\u20132015","volume":"95","author":"C Tacoli","year":"2016","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"pone.0354429.ref030","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01818-18","article-title":"Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda","volume":"63","author":"V Asua","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"pone.0354429.ref031","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3201\/eid2404.170141","article-title":"Artemisinin-Resistant Plasmodium falciparum with High Survival Rates, Uganda, 2014-2016","volume":"24","author":"M Ikeda","year":"2018","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"pone.0354429.ref032","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/infdis\/jiab352","article-title":"High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine","volume":"225","author":"J Straimer","year":"2022","journal-title":"J Infect Dis"},{"issue":"1","key":"pone.0354429.ref033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-019-2730-1","article-title":"Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania","volume":"18","author":"DS Ishengoma","year":"2019","journal-title":"Malar J"},{"issue":"6","key":"pone.0354429.ref034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0305064","article-title":"Day 3 parasitemia and Plasmodium falciparum Kelch 13 mutations among uncomplicated malaria patients treated with artemether-lumefantrine in Adjumani district, Uganda","volume":"19","author":"MK Angwe","year":"2024","journal-title":"PLoS One"},{"issue":"1","key":"pone.0354429.ref035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12936-023-04517-2","article-title":"Novel Plasmodium falciparum k13 gene polymorphisms from Kisii County, Kenya during an era of artemisinin-based combination therapy deployment","volume":"22","author":"JN Maniga","year":"2023","journal-title":"Malar J"},{"issue":"1","key":"pone.0354429.ref036","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3201\/eid2701.203527","article-title":"Increase in Kelch 13 Polymorphisms in Plasmodium falciparum, Southern Rwanda","volume":"27","author":"C Bergmann","year":"2021","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"pone.0354429.ref037","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12936-021-03636-y","article-title":"Assessment of Plasmodium falciparum anti-malarial drug resistance markers in pfk13-propeller, pfcrt and pfmdr1 genes in isolates from treatment failure patients in Democratic Republic of Congo, 2018-2019","volume":"20","author":"DM Yobi","year":"2021","journal-title":"Malar J"},{"key":"pone.0354429.ref038","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijid.2023.11.026","article-title":"Identification of the PfK13 mutations R561H and P441L in the Democratic Republic of Congo","volume":"139","author":"G Mesia Kahunu","year":"2024","journal-title":"Int J Infect Dis"},{"issue":"1","key":"pone.0354429.ref039","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12936-023-04812-y","article-title":"Molecular surveillance of Kelch 13 polymorphisms in Plasmodium falciparum isolates from Kenya and Ethiopia","volume":"23","author":"B Jeang","year":"2024","journal-title":"Malar J"},{"key":"pone.0354429.ref040","unstructured":"Akala H, Opot B, Juma DW, Okoth RO, Mwalo M, Salim FA, et al. Detection of twenty-four Plasmodium falciparum kelch 13 mutations including C469Y, P553L, R561H, and A675V across Kenya."},{"issue":"4","key":"pone.0354429.ref041","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.4269\/ajtmh.21-0214","article-title":"Therapeutic Efficacy of Artemisinin-Based Combination Therapies in Democratic Republic of the Congo and Investigation of Molecular Markers of Antimalarial Resistance","volume":"105","author":"LF Moriarty","year":"2021","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"pone.0354429.ref042","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12936-020-03287-5","article-title":"Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether-lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tanzania: a randomized controlled trial","volume":"19","author":"LE Mhamilawa","year":"2020","journal-title":"Malar J"},{"issue":"1","key":"pone.0354429.ref043","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/infdis\/jiae425","article-title":"Efficacy and safety of artemether-lumefantrine against uncomplicated falciparum malaria infection in Tanzania, 2022: a single-arm clinical trial","volume":"231","author":"JE Laury","year":"2025","journal-title":"J Infect Dis"},{"issue":"8","key":"pone.0354429.ref044","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3201\/eid2608.191547","article-title":"Increased Sensitivity of Plasmodium falciparum to Artesunate\/Amodiaquine Despite 14 Years as First-Line Malaria Treatment, Zanzibar","volume":"26","author":"M Msellem","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"pone.0354429.ref045","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12936-024-04896-0","article-title":"Trends of Plasmodium falciparum molecular markers associated with resistance to artemisinins and reduced susceptibility to lumefantrine in Mainland Tanzania from 2016 to 2021","volume":"23","author":"C Bakari","year":"2024","journal-title":"Malar J"},{"issue":"6","key":"pone.0354429.ref046","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/infdis\/jiaa687","article-title":"Changing Prevalence of Potential Mediators of Aminoquinoline, Antifolate, and Artemisinin Resistance Across Uganda","volume":"223","author":"V Asua","year":"2021","journal-title":"J Infect Dis"},{"key":"pone.0354429.ref047","first-page":"33","volume-title":"Antimalarial drug combination therapy. Report of a WHO technical consultation","author":"Organization WH","year":"2001"},{"issue":"8","key":"pone.0354429.ref048","first-page":"959","article-title":"Genomic epidemiology of artemisinin resistant malaria","volume":"48","author":"R Amato","year":"2016","journal-title":"Elife"},{"issue":"5","key":"pone.0354429.ref049","doi-asserted-by":"crossref","first-page":"101027","DOI":"10.1016\/j.lanmic.2024.101027","article-title":"Selection of Plasmodium falciparum kelch13 mutations in Uganda in comparison with southeast Asia: a modelling study","volume":"6","author":"CPG Meier-Scherling","year":"2025","journal-title":"Lancet Microbe"},{"issue":"4","key":"pone.0354429.ref050","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4269\/ajtmh.23-0740","article-title":"Detection of artemisinin resistance marker Kelch-13 469Y in Plasmodium falciparum, South Kivu, Democratic Republic of the Congo, 2022","volume":"110","author":"W van Loon","year":"2024","journal-title":"Am J Trop Med Hyg"},{"issue":"25","key":"pone.0354429.ref051","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1056\/NEJMoa1513137","article-title":"A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms","volume":"374","author":"D M\u00e9nard","year":"2016","journal-title":"N Engl J Med"},{"key":"pone.0354429.ref052","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12936-016-1095-y","article-title":"Lack of K13 mutations in Plasmodium falciparum persisting after artemisinin combination therapy treatment of Kenyan children","volume":"15","author":"J Muwanguzi","year":"2016","journal-title":"Malar J"},{"issue":"7","key":"pone.0354429.ref053","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3201\/eid2107.150213","article-title":"Slow Clearance of Plasmodium falciparum in Severe Pediatric Malaria, Uganda, 2011-2013","volume":"21","author":"M Hawkes","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"pone.0354429.ref054","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s41182-022-00466-9","article-title":"Self-medication and Anti-malarial Drug Resistance in the Democratic Republic of the Congo (DRC): A silent threat","volume":"50","author":"A Akilimali","year":"2022","journal-title":"Trop Med Health"},{"issue":"6","key":"pone.0354429.ref055","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1473-3099(12)70064-6","article-title":"Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa","volume":"12","author":"GM Nayyar","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"pone.0354429.ref056","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/978-0-387-89370-9_24","article-title":"Counterfeit and Substandard Anti-infectives in Developing Countries","volume-title":"Antimicrobial Resistance in Developing Countries","author":"PN Newton","year":"2010"},{"issue":"6","key":"pone.0354429.ref057","article-title":"A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies","volume":"77","author":"A Bosman","year":"2007","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"pone.0354429.ref058","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12936-018-2454-7","article-title":"Private sector drug shops frequently dispense parenteral anti-malarials in a rural region of Western Uganda","volume":"17","author":"LT Wang","year":"2018","journal-title":"Malar J"},{"issue":"1","key":"pone.0354429.ref059","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s12936-024-05158-9","article-title":"Emerging threat of artemisinin partial resistance markers (pfk13 mutations) in Plasmodium falciparum parasite populations in multiple geographical locations in high transmission regions of Uganda","volume":"23","author":"BB Agaba","year":"2024","journal-title":"Malar J"},{"key":"pone.0354429.ref060","doi-asserted-by":"crossref","first-page":"102684","DOI":"10.1016\/j.tmaid.2023.102684","article-title":"Artemisinin resistance-associated gene mutations in Plasmodium falciparum: A case study of severe malaria from Mozambique","volume":"57","author":"D Casanova","year":"2024","journal-title":"Travel Med Infect Dis"},{"issue":"1","key":"pone.0354429.ref061","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3201\/eid2401.170864","article-title":"Drug-Resistant Polymorphisms and Copy Numbers in Plasmodium falciparum, Mozambique, 2015","volume":"24","author":"H Gupta","year":"2018","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"pone.0354429.ref062","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12936-018-2524-x","article-title":"Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania","volume":"17","author":"MA Kakolwa","year":"2018","journal-title":"Malar J"},{"issue":"1","key":"pone.0354429.ref063","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12936-019-2730-1","article-title":"Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania","volume":"18","author":"DS Ishengoma","year":"2019","journal-title":"Malar J"},{"issue":"6","key":"pone.0354429.ref064","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/trstmh\/trz009","article-title":"Efficacy of artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria among children in Rwanda: an open-label, randomized controlled trial","volume":"113","author":"A Uwimana","year":"2019","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"7","key":"pone.0354429.ref065","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/infdis\/jiy637","article-title":"Comparative Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Ugandan Children","volume":"219","author":"A Yeka","year":"2019","journal-title":"J Infect Dis"},{"issue":"6","key":"pone.0354429.ref066","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/cid\/ciw388","article-title":"Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai\u2013Myanmar border (2003\u20132013): the role of parasite genetic factors","volume":"63","author":"AP Phyo","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0354429.ref067","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1473-3099(15)00487-9","article-title":"Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study","volume":"16","author":"C Amaratunga","year":"2016","journal-title":"Lancet Infect Dis"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0354429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:23:23Z","timestamp":1785259403000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0354429"}},"subtitle":[],"editor":[{"given":"Myat Htut","family":"Nyunt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":67,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0354429","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]}}}